dc.contributor.author | Othieno-Abinya, NA | |
dc.contributor.author | Nyabola, LO | |
dc.contributor.author | Nyong'o, AO | |
dc.contributor.author | Baraza, R | |
dc.date.accessioned | 2013-06-10T14:24:09Z | |
dc.date.available | 2013-06-10T14:24:09Z | |
dc.date.issued | 2001 | |
dc.identifier.citation | East Afr Med J. 2001 Jul;78(7):370-2. | en |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/pubmed/11957262 | |
dc.identifier.uri | http://erepository.uonbi.ac.ke:8080/xmlui/handle/123456789/30985 | |
dc.description.abstract | OBJECTIVE:
To determine the impact on neutrophils if adriamycin is administered at 60 mg/m2 and cyclophosphamide at 600/m2 (AC 60/600); and at 50 mg/m2 and 500 mg/m2 (50/500) in the treatment of breast cancer.
DESIGN:
Restrospective analysis of nadir neutrophil counts in female mammary carcinoma patients treated with adriamycin/cyclophosphamide combination.
SETTING:
Hurlingham Oncology Clinic, Nairobi and The Nairobi Hospital between March 1995 and August 1999.
SUBJECTS:
Eighteen patients with breast cancer were treated either for adjuvant purposes or for metastatic disease.
INTERVENTION:
Chemotherapy with adriamycin and cyclophosphamide at 60/600 or 50/500. Patients were advised to avoid crowded places and given prophylactic broadspectrum antibiotics whenever grade 4 neutropenia occurred at nadir.
RESULTS:
Grade 3-4 neutropenia occurred in 75.5% of treatments at 60/600 and in 56.8% of the treatments at 50/500. Febrile neutropenia followed only one treatment and did not result in death.
CONCLUSION:
Neutropenia is frequent and severe at A/C 60/600 and need to be watched out for. Sepsis on the other hand is prevented if meticulous attention is given and corrective measures taken. A/C 50/500 was associated with less occurrences of neutropenia though still very high. Neutropenia should therefore be checked and steps be taken to prevent sepsis even at this dosage. | en |
dc.language.iso | en | en |
dc.title | Nadir neutrophil counts in patients treated for breast cancer with doxorubicin and cyclophosphamide | en |
dc.type | Article | en |
local.publisher | College of health sciences,University of Nairobi | en |